 RADNOR, Pa., Aug. 23, 2021 PRNewswire -- NRx Pharmaceuticals NRx Nasdaq: NRXP, a clinical stage, biopharmaceutical company noted today reports1 in the Israeli media that participants in the BriLife vaccine trial who received the highest dose vaccine were notified by local health authorities they did not need a third, booster dose of the vaccine as their protection remained high, six months after getting a second dose. 